BRPI0513855A - células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus - Google Patents

células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus

Info

Publication number
BRPI0513855A
BRPI0513855A BRPI0513855-8A BRPI0513855A BRPI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A
Authority
BR
Brazil
Prior art keywords
trail
necrosis factor
related apoptosis
tumor
adenovirus
Prior art date
Application number
BRPI0513855-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg filed Critical Dompe Pha R Ma Spa Res & Mfg
Publication of BRPI0513855A publication Critical patent/BRPI0513855A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0513855-8A 2004-07-29 2005-07-21 células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus BRPI0513855A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
BRPI0513855A true BRPI0513855A (pt) 2008-05-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513855-8A BRPI0513855A (pt) 2004-07-29 2005-07-21 células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus

Country Status (24)

Country Link
US (1) US20070264231A1 (cg-RX-API-DMAC7.html)
EP (2) EP1621550A1 (cg-RX-API-DMAC7.html)
JP (1) JP5042826B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070047757A (cg-RX-API-DMAC7.html)
CN (1) CN101076540B (cg-RX-API-DMAC7.html)
AT (1) ATE455847T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005266543B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0513855A (cg-RX-API-DMAC7.html)
CA (1) CA2571426A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005019050D1 (cg-RX-API-DMAC7.html)
DK (1) DK1771468T3 (cg-RX-API-DMAC7.html)
ES (1) ES2340400T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100227T1 (cg-RX-API-DMAC7.html)
IL (1) IL180233A (cg-RX-API-DMAC7.html)
MX (1) MX2007001152A (cg-RX-API-DMAC7.html)
NO (1) NO20070956L (cg-RX-API-DMAC7.html)
NZ (1) NZ552223A (cg-RX-API-DMAC7.html)
PL (1) PL1771468T3 (cg-RX-API-DMAC7.html)
PT (1) PT1771468E (cg-RX-API-DMAC7.html)
RS (1) RS51381B (cg-RX-API-DMAC7.html)
RU (1) RU2390558C2 (cg-RX-API-DMAC7.html)
SI (1) SI1771468T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006010558A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701231B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014784A (es) * 2004-06-18 2007-04-25 Genentech Inc Metodos para utilizar agonistas del receptor apo-2l y actividadores de celulas nk.
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
ES2970269T3 (es) * 2015-07-29 2024-05-27 Onk Therapeutics Ltd Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
KR20210142665A (ko) 2019-03-21 2021-11-25 오엔케이 테라퓨틱스 리미티드 세포 사멸에 대한 증가된 내성을 갖는 변형된 면역 효과기 세포
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
CN1744919A (zh) * 2000-09-11 2006-03-08 南卡罗莱纳医科大学研究发展基金会 使用凋亡的选择性诱导来治疗肿瘤的方法和组合物
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
EP1771468B1 (en) 2010-01-20
DE602005019050D1 (de) 2010-03-11
IL180233A0 (en) 2007-07-04
HRP20100227T1 (hr) 2010-07-31
AU2005266543A1 (en) 2006-02-02
JP5042826B2 (ja) 2012-10-03
US20070264231A1 (en) 2007-11-15
RS51381B (sr) 2011-02-28
JP2008507961A (ja) 2008-03-21
NO20070956L (no) 2007-02-20
PT1771468E (pt) 2010-04-20
CN101076540B (zh) 2012-10-24
EP1621550A1 (en) 2006-02-01
RU2390558C2 (ru) 2010-05-27
PL1771468T3 (pl) 2010-07-30
IL180233A (en) 2010-12-30
CA2571426A1 (en) 2006-02-02
SI1771468T1 (sl) 2010-07-30
EP1771468A1 (en) 2007-04-11
MX2007001152A (es) 2007-04-18
NZ552223A (en) 2009-01-31
ATE455847T1 (de) 2010-02-15
RU2007107369A (ru) 2008-09-10
AU2005266543B2 (en) 2012-02-02
ZA200701231B (en) 2008-08-27
WO2006010558A8 (en) 2006-08-24
ES2340400T3 (es) 2010-06-02
HK1110874A1 (en) 2008-07-25
KR20070047757A (ko) 2007-05-07
DK1771468T3 (da) 2010-05-25
WO2006010558A1 (en) 2006-02-02
CN101076540A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
BRPI0513855A (pt) células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus
BRPI0418805B8 (pt) construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos
Nakagawa et al. Promotion of direct reprogramming by transformation-deficient Myc
TW200611974A (en) Chimeric adenoviruses for use in cancer treatment
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
EP1632499A3 (en) Gene sequences amplified in tumours and their diagnostic uses
MX2020011789A (es) Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
Jäger et al. The enigmatic roles of caspases in tumor development
WO2007073489A3 (en) Molecules for gene delivery and gene therapy, and methods of use thereof
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
EP1683811A3 (en) Compositions and methods for the treatment of tumors
WO2009097014A3 (en) Therapeutic kinase modulators
Lee et al. Adenine nucleotide translocase 2 as an enzyme related to [18F] FDG Accumulation in Various Cancers
ES2329689T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
Duro de Oliveira et al. Higher incidence of lung adenocarcinomas induced by DMBA in connexin 43 heterozygous knockout mice
WO2008067025A3 (en) Oncolytic adenoviruses and uses thereof
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
WO2010006136A3 (en) Adenovirus targeting
WO2023031215A3 (en) Pro-apoptotic construct and use thereof
WO2008021211A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
ATE512159T1 (de) Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DOMPE' S.P.A. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: DOMPE PHA.R.MA S.P.A.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 35/12 (2015.01)